Since NK‐1R antagonists exert a potent antitumor action through distinct mechanisms from chemotherapeutic drugs, we hypothesized that use of a combination of NK‐1R antagonists will improve its efficacy and reduce the incidence of chemotherapy‐induced toxicity in patients with colon cancer. Here, TACR1 is linked to malignant colon neoplasm.